Lanreotide
Also known as: Somatuline Depot, Somatuline Autogel, BIM 23014
A long-acting somatostatin analog for acromegaly and neuroendocrine tumors. FDA-approved as Somatuline Depot since 2007. Prescription medication.
Last updated
Mechanism of Action
Lanreotide is a cyclic octapeptide somatostatin analog with high affinity for somatostatin receptor subtypes 2 and 5. Binding inhibits growth hormone secretion from the pituitary, lowering IGF-1, and suppresses release of serotonin and other hormones from neuroendocrine tumors. It also has antiproliferative effects on gastroenteropancreatic neuroendocrine tumors. The depot formulation self-assembles into a gel after deep subcutaneous injection, releasing drug over about a month.
- Half-life
- ~23 to 30 days (depot formulation)
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Approved for long-term treatment of acromegaly
- Approved to improve progression-free survival in unresectable gastroenteropancreatic neuroendocrine tumors (CLARINET)
- Approved to reduce the need for short-acting rescue therapy in carcinoid syndrome
Potential Side Effects
- Diarrhea, abdominal pain, nausea and flatulence
- Gallstones
- Injection-site reactions
- High or low blood glucose
- Bradycardia
Common Dosing
Labeled dosing is a deep subcutaneous injection every 4 weeks, given by a healthcare provider or a trained patient or caregiver; the dose depends on the indication and, in acromegaly, on hormone levels. Dosing is set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Known hypersensitivity to lanreotide
- Use with caution in gallbladder disease, diabetes and cardiac conduction disorders
- View
Lanreotide in metastatic enteropancreatic neuroendocrine tumors
2014
- View
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
2010